Prior antithrombotic therapy, n (%) Yes 3,789 (71.7) 1838 389 (56.4) 1,426 (63.9) 141 (42.2) No 1,498 (28.3) (71.3)739 301 (43.6) 807 (36.1) 193 (57.8) (28.7) Type of prior antithrombotic therapy, n (%) VKA 2,035 (38.5) 996 (38.6) 221 (30.6) 803 (36.0) 74 (22.2) DTI 158 (3.0) 66 (2.6) 44 (6.4) 149 (6.7) 10 (3.0) Factor Xa inhibitor (excluding 7 (0.1) 5 (0.2) 0 (0.0) 1 (<0.05) 4 (1.2) rivaroxaban) ASA (excluding DAPT) 967 (18.3) 540 (21.0) 96 (13.9) 356 (15.9) 45 (13.5) DAPT 53 (1.0) 26 (1.0) 14 (2.0) 20 (0.9) 2 (0.6) Heparin 174 (3.3) 73 (2.8) 4 (0.6) 10 (0.4) 3 (0.9) Other antithrombotics 55 (1.0) 6 (0.2) 1 (0.1) 18 (0.8) 0 (0.0) Multiple 340 (6.4) 126 (4.9) 19 (2.8) 69 (3.1) 3 (0.9)
Prior antithrombotic therapy, n (%) Yes No 3,789 (71.7) 1,498 (28.3) 1838 (71.3)739 (28.7) 389 (56.4) 301 (43.6) 1,426 (63.9) 807 (36.1) 141 (42.2) 193 (57.8) Type of prior antithrombotic therapy, n (%) VKA DTI Factor Xa inhibitor (excluding rivaroxaban) ASA (excluding DAPT) DAPT Heparin Other antithrombotics Multiple 2,035 (38.5) 158 (3.0) 7 (0.1) 967 (18.3) 53 (1.0) 174 (3.3) 55 (1.0) 340 (6.4) 996 (38.6) 66 (2.6) 5 (0.2) 540 (21.0) 26 (1.0) 73 (2.8) 6 (0.2) 126 (4.9) 221 (30.6) 44 (6.4) 0 (0.0) 96 (13.9) 14 (2.0) 4 (0.6) 1 (0.1) 19 (2.8) 803 (36.0) 149 (6.7) 1 (<0.05) 356 (15.9) 20 (0.9) 10 (0.4) 18 (0.8) 69 (3.1) 74 (22.2) 10 (3.0) 4 (1.2) 45 (13.5) 2 (0.6) 3 (0.9) 0 (0.0) 3 (0.9)
1-s2.0-S0735109718347958-mmc1.docx